This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Dividend Stars Portfolio: December Update

Stocks in this article: NVSFXPDENSCINTCXOM

-----------------------------

Other Notable News:

Novartis (NVS) had a good month (up 4.75%); in spite of some negative news regarding its blood pressure drug Tekturna. The company announced that they were ending a recently concluded study of the drug for high-risk patients with diabetes and renal impairment. The study was terminated early due to patient safety concerns. There were thoughts that the drug could be a future blockbuster for Novartis, but now it's more likely that the drug could be sold or taken off the market. Tekturna accounts for roughly 1% of sales for NVS, and has not turned a profit as of yet. JP Morgan analysts have noted that the news might not be the end of the world, and could result in "substantial cuts to the investment behind Tekturna, with upside to 2012 and 2013 margins." The stock remains a conviction pick, as its strong pipeline and diversified business line (which includes generic business Sandoz and eye care company Alcon) should help support the upcoming patent expiration of Diovan in 2012.

-----------------------------

Portfolio Returns (Dec 1st to Dec 31st):


Proshares Ultrashort FTSE (FXP): +8.58%
Exxon Mobil (XOM): +6.23%
McGraw Hill (MHP): +5.07%
Novartis (NVS): +4.75%
Proctor & Gamble (PG): +4.1%
Chubb (CB): +3.93%
PepsiCo (PEP): +3.53%
Microsoft (MSFT): +2.69%
Honeywell (HON): +0.33%
Deere (DE): -1.23%
Target (TGT): -1.78%
Norfolk Southern (NSC): -2.57%
Intel (INTC): -2.69%
Mattel (MAT): -3.38%

If you have any questions, comments or suggestions, feel free to message me on Twitter at @bostoncfa

Equity research manager Chris Stuart, CFA, joined TheStreet Ratings after working as a senior investment analyst with Merrill Lynch covering small-cap equity and alternative investment strategies. Prior to that, Stuart worked for One Beacon Insurance as an actuarial analyst and at H&R Block as a financial adviser. Stuart earned his bachelor's degree in finance from the University of Massachusetts, Amherst. He holds a Chartered Financial Analyst (CFA) designation and is a member of the Boston Security Analysts Society (BSAS) and the CFA Institute.
2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,800.59 -9.47 -0.05%
S&P 500 2,067.55 +4.05 0.20%
NASDAQ 4,748.8650 +35.8950 0.76%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs